Cover Image
Market Research Report
Product code
987692

Oncolytic Virus Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Published: | Transparency Market Research | 182 Pages | Delivery time: 1-2 business days

Price

Back to Top
Oncolytic Virus Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030
Published: October 1, 2020
Transparency Market Research
Content info: 182 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Title:
Oncolytic Virus Immunotherapy Market (Type: Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Others; Route of Administration: Intratumoral and Intravenous; and Application: Melanoma, Non-small Cell Lung Cancer [NSCLC], Pancreatic Cancer, Breast Cancer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030.

Oncolytic Virus Immunotherapy Market - Scope of the Report

TMR's report on the global oncolytic virus immunotherapy market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global oncolytic virus immunotherapy market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global oncolytic virus immunotherapy market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involves bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global oncolytic virus immunotherapy market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global oncolytic virus immunotherapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global oncolytic virus immunotherapy market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global oncolytic virus immunotherapy market.

The report delves into the competition landscape of the global oncolytic virus immunotherapy market. Key players operating in the global oncolytic virus immunotherapy market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global oncolytic virus immunotherapy market that have been profiled in this report.

Key Questions Answered in Oncolytic Virus Immunotherapy Market Report

What is the scope of growth for product companies in the global oncolytic virus immunotherapy market?

What will be the Y-o-Y growth of the global oncolytic virus immunotherapy market between 2020 and 2030?

What is the influence of changing trends in technologies on the global oncolytic virus immunotherapy market?

Will North America continue to be the most profitable market for oncolytic virus immunotherapy?

Which factors are anticipated to hamper the global oncolytic virus immunotherapy market during the forecast period?

Which are the leading companies in the global oncolytic virus immunotherapy market?

Research Methodology

A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global oncolytic virus immunotherapy market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global oncolytic virus immunotherapy market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the oncolytic virus immunotherapy market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the oncolytic virus immunotherapy market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global oncolytic virus immunotherapy market with accuracy. The study also uses the top-down approach to assess the revenue of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global oncolytic virus immunotherapy more reliably and accurately

Table of Contents
Product Code: TMRGL44931

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Oncolytic Virus Immunotherapy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2018-2030

5. Key Insights

  • 5.1. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
  • 5.2. Pipeline Analysis
  • 5.3. Key Industry Developments
  • 5.4. Features of oncolytic viruses

6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018-2030
    • 6.3.1. Herpes Simplex Virus
    • 6.3.2. Vaccinia Virus
    • 6.3.3. Adenovirus
    • 6.3.4. Reovirus
    • 6.3.5. Others
  • 6.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type

7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018-2030
    • 7.3.1. Intratumoral
    • 7.3.2. Intravenous
  • 7.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration

8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018-2030
    • 8.3.1. Melanoma
    • 8.3.2. Non-small Cell Lung Cancer (NSCLC)
    • 8.3.3. Pancreatic Cancer
    • 8.3.4. Breast Cancer
    • 8.3.5. Others
  • 8.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application

9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Rest of World
  • 9.3. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Region

10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018-2030
    • 10.2.1. Herpes Simplex Virus
    • 10.2.2. Vaccinia Virus
    • 10.2.3. Adenovirus
    • 10.2.4. Reovirus
    • 10.2.5. Others
  • 10.3. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018-2030
    • 10.3.1. Intratumoral
    • 10.3.2. Intravenous
  • 10.4. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018-2030
    • 10.4.1. Melanoma
    • 10.4.2. Non-small Cell Lung Cancer (NSCLC)
    • 10.4.3. Pancreatic Cancer
    • 10.4.4. Breast Cancer
    • 10.4.5. Others
  • 10.5. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Country, 2018-2030
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis
    • 10.6.1. By Type
    • 10.6.2. By Route of Administration
    • 10.6.3. By Application
    • 10.6.4. By Country

11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018-2030
    • 11.2.1. Herpes Simplex Virus
    • 11.2.2. Vaccinia Virus
    • 11.2.3. Adenovirus
    • 11.2.4. Reovirus
    • 11.2.5. Others
  • 11.3. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018-2030
    • 11.3.1. Intratumoral
    • 11.3.2. Intravenous
  • 11.4. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018-2030
    • 11.4.1. Melanoma
    • 11.4.2. Non-small Cell Lung Cancer (NSCLC)
    • 11.4.3. Pancreatic Cancer
    • 11.4.4. Breast Cancer
    • 11.4.5. Others
  • 11.5. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018-2030
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis
    • 11.6.1. By Type
    • 11.6.2. By Route of Administration
    • 11.6.3. By Application
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018-2030
    • 12.2.1. Herpes Simplex Virus
    • 12.2.2. Vaccinia Virus
    • 12.2.3. Adenovirus
    • 12.2.4. Reovirus
    • 12.2.5. Others
  • 12.3. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018-2030
    • 12.3.1. Intratumoral
    • 12.3.2. Intravenous
  • 12.4. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018-2030
    • 12.4.1. Melanoma
    • 12.4.2. Non-small Cell Lung Cancer (NSCLC)
    • 12.4.3. Pancreatic Cancer
    • 12.4.4. Breast Cancer
    • 12.4.5. Others
  • 12.5. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018-2030
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis
    • 12.6.1. By Type
    • 12.6.2. By Route of Administration
    • 12.6.3. By Application
    • 12.6.4. By Country/Sub-region

13. Rest of World Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018-2030
    • 13.2.1. Herpes Simplex Virus
    • 13.2.2. Vaccinia Virus
    • 13.2.3. Adenovirus
    • 13.2.4. Reovirus
    • 13.2.5. Others
  • 13.3. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018-2030
    • 13.3.1. Intratumoral
    • 13.3.2. Intravenous
  • 13.4. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018-2030
    • 13.4.1. Melanoma
    • 13.4.2. Non-small Cell Lung Cancer (NSCLC)
    • 13.4.3. Pancreatic Cancer
    • 13.4.4. Breast Cancer
    • 13.4.5. Others
  • 13.5. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018-2030
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis
    • 13.6.1. By Type
    • 13.6.2. By Route of Administration
    • 13.6.3. By Application
    • 13.6.4. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis/Ranking, by Company, 2019
  • 14.3. Company Profiles
    • 14.3.1. Amgen Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Company Financials
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Merck & Co., Inc. (Viralytics Limited)
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Shanghai Sunway Biotech Co., Ltd
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Growth Strategies
      • 14.3.3.3. SWOT Analysis
    • 14.3.4. TILT Biotherapeutics
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Growth Strategies
      • 14.3.4.3. SWOT Analysis
    • 14.3.5. Oncorus, Inc.
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Growth Strategies
      • 14.3.5.3. SWOT Analysis
    • 14.3.6. Replimune Group, Inc.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Oncolys BioPharma, Inc.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Sorrento Therapeutics, Inc.
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Company Financials
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Oncolytics Biotech, Inc.
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Company Financials
      • 14.3.9.3. Growth Strategies
      • 14.3.9.4. SWOT Analysis
    • 14.3.10. SillaJen, Inc.
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Growth Strategies
      • 14.3.10.3. SWOT Analysis

List of Table

  • Table 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 02: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 03: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 04: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2018-2030
  • Table 05: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country, 2018-2030
  • Table 06: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018-2030
  • Table 07: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 08: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018-2030
  • Table 09: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 10: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018-2030
  • Table 11: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 12: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018-2030
  • Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018-2030
  • Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018-2030
  • Table 17: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018-2030
  • Table 18: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 19: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018-2030

List of Figure

  • Figure 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 02: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2019
  • Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2019
  • Figure 04: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2019
  • Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2019
  • Figure 06: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 07: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 08: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Herpes Simplex Virus, 2018-2030
  • Figure 09: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Vaccinia Virus, 2018-2030
  • Figure 10: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Adenovirus, 2018-2030
  • Figure 11: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Reovirus, 2018-2030
  • Figure 12: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018-2030
  • Figure 13: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 14: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 15: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intratumoral, 2018-2030
  • Figure 16: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intravenous, 2018-2030
  • Figure 17: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2019 and 2030
  • Figure 18: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020-2030
  • Figure 19: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Melanoma, 2018-2030
  • Figure 20: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Non-small Cell Lung Cancer (NSCLC), 2018-2030
  • Figure 21: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Pancreatic Cancer, 2018-2030
  • Figure 22: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Breast Cancer, 2018-2030
  • Figure 23: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018-2030
  • Figure 24: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2019 and 2030
  • Figure 25: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region
  • Figure 26: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 27: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Country, 2019 and 2030
  • Figure 28: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2020-2030
  • Figure 29: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030
  • Figure 30: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 31: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030
  • Figure 32: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 33: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030
  • Figure 34: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020-2030
  • Figure 35: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 36: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030
  • Figure 37: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 38: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030
  • Figure 39: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 40: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030
  • Figure 41: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 42: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030
  • Figure 43: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020-2030
  • Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 45: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030
  • Figure 46: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 47: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030
  • Figure 48: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 49: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030
  • Figure 50: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 51: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030
  • Figure 52: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020-2030
  • Figure 53: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 54: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2021 and 2030
  • Figure 55: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2022-2030
  • Figure 56: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2021 and 2030
  • Figure 57: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2022-2030
  • Figure 58: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2021 and 2030
  • Figure 59: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022-2030
  • Figure 60: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019
  • Figure 61: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2019
  • Figure 62: Amgen, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019
  • Figure 63: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019
  • Figure 64: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2019
  • Figure 65: Merck & Co., Inc. Breakdown of Net Sales (%), by Business Segment, 2019
  • Figure 66: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019
  • Figure 67: Replimune Group, Inc. Total Operating Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2020
  • Figure 68: Replimune Group, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2019
  • Figure 69: Oncolys BioPharma, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019
  • Figure 70: Oncolys BioPharma, Inc. Breakdown of Net Sales (%), by Region/Country, 2019
  • Figure 71: Sorrento Therapeutics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019
  • Figure 72: Sorrento Therapeutics, Inc. Breakdown of Net Sales (%), by Business Segment, 2019
  • Figure 73: Sorrento Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019
  • Figure 74: Oncolytics Biotech, Inc. Total assets (US$ Mn) and Y-o-Y Growth (%), 2017-2019
  • Figure 75: Oncolytics Biotech, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019